AGREEMENT FOR REIMBURSEMENT OF CAPITAL EXPENDITURE AND SERVICE FEES BETWEEN AESICA QUEENBOROUGH LIMITED And OPIANT PHARMACEUTICALS INC relating to the development, manufacture and supply of a device capable of administering Nalmefene hydrochlorideAgreement for Reimbursement of Capital Expenditure and Service Fees • September 10th, 2018 • Opiant Pharmaceuticals, Inc. • Metal mining • Delaware
CONFIDENTIALTREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION DATED: SEPTEMBER 7, 2018 AESICA QUEENBOROUGH LIMITED and OPIANT PHARMACEUTICALS INC...Development Agreement • September 10th, 2018 • Opiant Pharmaceuticals, Inc. • Metal mining • Delaware
